•   
  •   

Health GSK to launch late-stage testing of syncytial virus vaccine

08:35  21 october  2020
08:35  21 october  2020 Source:   reuters.com

Michelle Bridges looks tense on Celebrity Apprentice Australia set

  Michelle Bridges looks tense on Celebrity Apprentice Australia set Celebrity Apprentice Australia is known for its ego-clashing dramas, tense showdowns and nail-biting boardroom 'firings'.And Michelle Bridges looked like she's already had enough as she arrived on the Nine show's Sydney set on Thursday.

World’s largest vaccine makers to begin testing on people in US with eye on rollout in early 2021.

The launch of phase 1 and 2 trials represent an "important stage and another step towards the development of a potential vaccine to help us beat A protein-based vaccine owned by Sanofi and used to treat influenza was paired with a GSK -developed add-on, known as an adjuvant, that boosts

A GSK logo is seen on a flag at a GSK research centre in Stevenage © Reuters/PETER NICHOLLS A GSK logo is seen on a flag at a GSK research centre in Stevenage FRANKFURT (Reuters) - GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage trial results.

RSV vaccine development has been fraught with setbacks for decades but the pharma industry is gearing up to bring a first inoculation to market over the next few years.

The area is a key growth opportunity for GSK, as it seeks to offset declining sales of its blockbuster lung drug Advair due to generic competition.

'On brink of disaster': shaken Europe battles COVID surge

  'On brink of disaster': shaken Europe battles COVID surge 'On brink of disaster': shaken Europe battles COVID surgePRAGUE/BRUSSELS (Reuters) - European nations are extending restrictions well beyond social life to close schools, cancel surgeries and enlist legions of student medics as overwhelmed authorities face their nightmare scenario of a COVID-19 resurgence at the onset of winter.

GSK and Sanofi plan to combine drugs they each produce in a bid to create an effective solution to stop the virus in its tracks. The vaccine will be developed by Sanofi and GSK aim to start early clinical trials later this year and hope regulatory approval might be possible later next year. UK-based GSK 's

Jul.31 -- The Trump administration will provide as much as .1 billion to Covid-19 vaccine partners Sanofi and GlaxoSmithKline Plc, the biggest U.S

GSK said a Phase I/II trial with about 1,000 healthy adults aged 60-80 showed that the vaccine prompted a "robust" increase in antibodies and immune cells one month after injection, indicating a stimulated immune system.


Gallery: The deadly beauty of viruses and bacteria (StarsInsider)

Far too small to be seen by the human eye, viruses and bacteria are identified by being placed under the microscope by scientists who use false color to enhance the detail of these infectious agents and single-cell organisms. The resulting images appear as miniature works of vibrant abstract art that could grace the walls of any contemporary gallery. Except in real life you wouldn't want to be anywhere near this harmful subject matter!Click through the following gallery and take a microscopic look at these killers in color.

A separate product, designed to give pregnant women the ability to confer immunity to their unborn children, led to high levels of protective neutralising antibodies in non-pregnant healthy woman taking part in a Phase I/II trial.

GSK said Phase III studies, with the potential to produce data for regulatory approval, would likely start over the coming months.

The vaccines were well-tolerated with side effects including injection-site pain and headache, GSK added.

14 Celebrities Who Worked For Other Stars Before Hitting It Big

  14 Celebrities Who Worked For Other Stars Before Hitting It Big Humble beginnings.

GlaxoSmithKline CEO calls coronavirus vaccine partnership with Sanofi an 'unprecedented collaboration'. GlaxoSmithKline CEO Emma Walmsley told Jim Cramer that GSK 's new Covid-19 vaccine Clinical trials are scheduled to begin later this year. The global count of coronavirus cases

Respiratory Syncytial Virus Infections. Biological: RSV_PreF3 Vaccine ( GSK 3844766A) adjuvanted with AS01B Drug: Placebo. Phase I, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK 's Respiratory Syncytial Virus (RSV) Vaccine GSK 3844766A in Japanese Subjects

Companies including Johnson & , Sanofi and Moderna are competing to get a vaccine approved against RSV, which globally leads to about 3 million hospital stays for children under five per year. Swedish Orphan Biovitrum's Synagis, a monthly shot, is currently the only preventive treatment against RSV in high-risk infants. Sanofi and partner AstraZeneca are working on longer-acting nirsevimab, which could be given once per cold season to that group, if approved.

GSK is also conducting early-stage studies of an RSV vaccine for children and plans to publish results some time between Oct. 26-29 for a subgroup of children which already had some exposure to the virus.

(Reporting by Ludwig Burger. Editing by Jane Merriman)

Energy renovation: the new advantages of MaPrimeRénov '.
© Peter Dazeley / Getty images Energy renovation: the new advantages of MaPrimeRénov' In this month's "Big real estate meeting" (Capital / Radio Immo) October, the Minister of Housing, Emmanuelle Wargon, discusses the launch of the new version of MaPrimeRénov '. The Minister of Housing, Emmanuelle Wargon was this month the guest of the "Great real estate meeting". The opportunity to come back in detail on the launch of the new version of MaPrimeRénov ’.

usr: 0
This is interesting!